BioInsights - Complete system for AAV production for clinical production: Part 1 Upstream
Jun
28
2022
On demand

Complete system for AAV production for clinical production: Part 1 Upstream

Sponsor
Complete system for AAV production for clinical production: Part 1 Upstream

AAV manufacturing challenges have been extensively discussed for several years. With a limited biological understanding of recombinant vector production and the limited amount of time developers have to optimize, scale, and qualify their manufacturing process, flexible solutions that can adapt to several vectors, cell lines, or facilities are needed. Thermo Fisher Scientific has answered this need with systems, reagents, and equipment that meet the needs of this fast-moving industry. During part one of this two-part webinar series, Jon Zmuda will present the upstream workflow of AAV production including cell culture, transfection, viral production and AAV extraction with the CTS™ AAV-MAX Helper Free AAV Production System. Specifically, we will cover:

  • The ability of CTS AAV-MAX to enable scalable, high-titer, and simplified AAV production with limited optimization needed
  • Studies that demonstrate the performance and scalability of the CTS AAV-MAX system in 50-L Thermo Scientific™ HyPerforma™ DynaDrive™ Single-Use Bioreactors.
  • What purification info will we be able to address in the webinar?
  • How downstream process challenges can be addressed through optimized AAV purification

Attend this webinar to:

  • Find out how to enable scalable, high-titer, and simplified AAV production with limited optimization needed
  • Discover flexible workflow solutions adaptable to different AAV serotypes, cell lines, or facilities
  • Receive Case Studies demonstrating the performance and scalability of the CTS™ AAV-MAX system in 50 L single-use bioreactors

Jenny England, PhD

Application Scientist and Innovation Leader, Thermo Fisher Scientific

Dr. Jenny England is a Staff Scientist in the Applications and Innovation group in Purification and Pharma Analytics at Thermo Fisher Scientific. Jenny is a biophysicist by training and earned her Ph.D. from Georgetown University. After graduate school, she did a post doc at the National Cancer Institute that focused on structure-based drug design for protein kinase complexes. Jenny currently leads the application group for process development of the POROS resin products for antibody, mRNA, plasmid, and viral vector purification. Additionally, Jenny evaluates new and emerging technologies that can be applied to solve unmet customer needs in the bioproduction workflow.

Jon Zmuda, PhD

Director, Cell Biology, Thermo Fisher Scientific 

Jonathan Zmuda, Ph.D. is a Director of Cell Biology R&D within the Biosciences Division of Thermo Fisher Scientific located in Frederick, MD (USA). Within Cell Biology, Jon leads various teams that focus on developing new technologies for protein expression, viral vector production, transfection and classical cell culture. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.

SPEAKERS

Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
Jonathan Zmuda
Jonathan Zmuda
Director, Cell Biology

You might also like